Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
CONCLUSIONS: The results of this study demonstrated that AE signals differ among the five BCR-ABL1 TKIs. Furthermore, each BCR-ABL1 TKI displayed several new signals. These findings provide valuable information for clinicians aiming to reduce the risk of AEs during BCR-ABL1 TKI treatment.PMID:38395895 | PMC:PMC10885429 | DOI:10.1186/s40360-024-00741-x (Source: BMC Pharmacology and Toxicology)
Source: BMC Pharmacology and Toxicology - February 23, 2024 Category: Drugs & Pharmacology Authors: Dehua Zhao Xiaoqing Long Jisheng Wang Source Type: research
The effect of oral supplementation of Paricalcitol on C-reactive protein levels in chronic kidney disease patients: GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials
CONCLUSION: Oral paricalcitol supplementation in CKD patients can significantly reduce C-reactive protein levels, which may prevent CKD progression.PMID:38395972 | PMC:PMC10885610 | DOI:10.1186/s40360-024-00740-y (Source: BMC Pharmacology and Toxicology)
Source: BMC Pharmacology and Toxicology - February 23, 2024 Category: Drugs & Pharmacology Authors: Seyyed Mostafa Arabi Mostafa Shahraki-Jazinaki Mahla Chambari Leila Sadat Bahrami Sara Sabeti Mohammaed Ibrahim Mohaildeen Gubari Basil D Roufogalis Amirhossein Sahebkar Source Type: research
New tricks for old drugs- praziquantel ameliorates bleomycin-induced pulmonary fibrosis in mice
CONCLUSIONS: Our study demonstrated that PZQ could ameliorate BLM-induced pulmonary fibrosis in mice by affecting the balance of M2/M1 macrophages and suppressing the expression of TGF-β and MMP-12. These findings suggest that PZQ may act as an effective anti-fibrotic agent for preventing the progression of pulmonary fibrosis.PMID:38355586 | PMC:PMC10868045 | DOI:10.1186/s40360-024-00737-7 (Source: BMC Pharmacology and Toxicology)
Source: BMC Pharmacology and Toxicology - February 14, 2024 Category: Drugs & Pharmacology Authors: Yanjun Zeng Rui Hu Wei Ma Ying Ding Yi Zhou Xin Peng Lixin Feng Qingmei Cheng Ziqiang Luo Source Type: research
New tricks for old drugs- praziquantel ameliorates bleomycin-induced pulmonary fibrosis in mice
CONCLUSIONS: Our study demonstrated that PZQ could ameliorate BLM-induced pulmonary fibrosis in mice by affecting the balance of M2/M1 macrophages and suppressing the expression of TGF-β and MMP-12. These findings suggest that PZQ may act as an effective anti-fibrotic agent for preventing the progression of pulmonary fibrosis.PMID:38355586 | DOI:10.1186/s40360-024-00737-7 (Source: BMC Pharmacology and Toxicology)
Source: BMC Pharmacology and Toxicology - February 14, 2024 Category: Drugs & Pharmacology Authors: Yanjun Zeng Rui Hu Wei Ma Ying Ding Yi Zhou Xin Peng Lixin Feng Qingmei Cheng Ziqiang Luo Source Type: research
Safinamide, an inhibitor of monoamine oxidase, modulates the magnitude, gating, and hysteresis of sodium ion current
CONCLUSION: SAF may interact directly with NaV channels in pituitary neuroendocrine cells, modulating membrane excitability.PMID:38331833 | PMC:PMC10851555 | DOI:10.1186/s40360-024-00739-5 (Source: BMC Pharmacology and Toxicology)
Source: BMC Pharmacology and Toxicology - February 8, 2024 Category: Drugs & Pharmacology Authors: Te-Yu Hung Sheng-Nan Wu Chin-Wei Huang Source Type: research
Large variation in anti-factor Xa levels with nadroparin as thromboprophylaxis in COVID-19 and non-COVID-19 critically ill patients
CONCLUSION: A standard nadroparin dosage of 2850 IU sc in the critically ill patient is not sufficient to attain target anti-FXa levels in the majority of the studied patient group. We suggest a standard higher dosage in combination with body-weight dependent dosing as it leads to better exposure to nadroparin.CLINICAL TRIALS REGISTRATION: Retrospectively registered, ClinicalTrials.gov ID NTC 05926518 g, date of registration 06/01/23, unique ID 2020/1725.PMID:38321487 | PMC:PMC10848501 | DOI:10.1186/s40360-024-00733-x (Source: BMC Pharmacology and Toxicology)
Source: BMC Pharmacology and Toxicology - February 6, 2024 Category: Drugs & Pharmacology Authors: Monique M R de Maat Henk J van Leeuwen Lian Roovers Sabine J G M Ahlers Jolanda Lambers Marcel M C Hovens Source Type: research
Determination of the median lethal dose of zinc gluconate in mice and safety evaluation
CONCLUSION: The appropriate dose range of ZG for intravenous injection in C57BL/6J mice was clarified, providing a reference for future experimental research.PMID:38317260 | PMC:PMC10840281 | DOI:10.1186/s40360-024-00736-8 (Source: BMC Pharmacology and Toxicology)
Source: BMC Pharmacology and Toxicology - February 5, 2024 Category: Drugs & Pharmacology Authors: Yong-Cai Wang Xia Yang Juan Xiao Su-Mei Wei Ying Su Xiu-Qi Chen Ting Huang Qing-Wen Shan Source Type: research
Role of uranium toxicity and uranium-induced oxidative stress in advancing kidney injury and endothelial inflammation in rats
CONCLUSION: The uranium-induced oxidative injury may be mainly reflected in enhanced endothelial inflammation, and the direct chemical toxicity of uranium plays an important role in the process of kidney injury, especially in renal tubular injury. In addition, CysC may be a sensitive marker reflecting the nephrotoxicity of uranium; however, Hcy is not suitable for evaluating short-term endothelial inflammation involving oxidative stress.PMID:38308341 | PMC:PMC10837886 | DOI:10.1186/s40360-024-00734-w (Source: BMC Pharmacology and Toxicology)
Source: BMC Pharmacology and Toxicology - February 3, 2024 Category: Drugs & Pharmacology Authors: Yuwei Yang Chunmei Dai Xi Chen Bin Zhang Xiaohan Li Wenyu Yang Jun Wang Jiafu Feng Source Type: research
Drug-drug interaction assessment based on a large-scale spontaneous reporting system for hepato- and renal-toxicity, and thrombocytopenia with concomitant low-dose methotrexate and analgesics use
CONCLUSIONS: Studies using spontaneous reporting systems have limitations such as reporting bias or lack of patient background; however, the results of our comprehensive analysis support the results of previous clinical or epidemiological studies. This study also demonstrated the usefulness of FAERS for DDI assessment.PMID:38303016 | PMC:PMC10832291 | DOI:10.1186/s40360-024-00738-6 (Source: BMC Pharmacology and Toxicology)
Source: BMC Pharmacology and Toxicology - February 2, 2024 Category: Drugs & Pharmacology Authors: Takeshi Honma Kenji Onda Koichi Masuyama Source Type: research
